MedTrace Logo

Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion

NCT03709745 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2024-10-28

No results posted yet for this study

Summary

Comparing time to recurrence of macular edema after an initial loading dose of at least three monthly anti VEGF injections (aflibercept or ranibizumab) for macular edema in BRVO.

Conditions

  • Branch Retinal Vein Occlusion with Macular Edema

Interventions

DRUG

Aflibercept Injection [Eylea]

Intravitreal injection is given as described in the arm description

DRUG

Ranibizumab Injection [Lucentis]

Intravitreal injection is given as described in the arm description

Sponsors & Collaborators

  • St. Erik Eye Hospital

    lead OTHER

Principal Investigators

  • Anders Kvanta, MD PhD · St. Erik Eye Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-18
Primary Completion
2021-10-15
Completion
2022-07-10

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03709745 on ClinicalTrials.gov